A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
- Resource Type
- Article
- Source
- In
Annals of Oncology May 2021 32(5):652-660 - Subject
Breast tumors - Language
- ISSN
- 0923-7534